Model-Based Cost-Effectiveness Analyses for the Treatment of Acute Stroke Events: A Review and Summary of Challenges

被引:17
|
作者
Earnshaw, Stephanie R. [1 ]
Wilson, Michele [1 ]
Mauskopf, Josephine [1 ]
Joshi, Ashish V. [2 ]
机构
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
[2] Novo Nordisk Inc, Princeton, NJ USA
关键词
cost-effectiveness analysis; decision analysis; stroke outcomes; systematic review; TISSUE-PLASMINOGEN ACTIVATOR; ACUTE ISCHEMIC-STROKE; QUALITY-OF-LIFE; RESOURCE UTILIZATION; ECONOMIC-MODEL; FACTOR-VII; CARE; THROMBOLYSIS; THERAPY; UTILITY;
D O I
10.1111/j.1524-4733.2008.00467.x
中图分类号
F [经济];
学科分类号
02 ;
摘要
To summarize the methodological approaches used in published decision-analytic models evaluating interventions for acute stroke treatment, to highlight key components of decision-analytic models of stroke treatment, and to discuss challenges for developing stroke decision models. A review of the published literature was performed using Medline, to identify studies involving mathematical decision models to evaluate interventions for acute stroke treatment. Articles were analyzed to determine key components of a stroke model and to note areas in which data are lacking. We identified 13 published models of acute stroke treatment. These models typically possessed a short-term treatment module and a long-term post-treatment module. The following aspects of economic modeling were found to be relevant for developing a stroke model: modeling approach and health state; health state transition probabilities; estimation of short-term, long-term, and indirect costs; health state utilities; poststroke mortality; time horizon; model validation; and estimation of parameter uncertainty. Data gaps have limited the development of economic models in stroke to date. In order to more accurately assess the long-term incremental impact of a new treatment of stroke, future research is needed to address these data gaps. We recommend that the complexity of models for examining the cost-effectiveness of an acute stroke treatment be kept to a minimum such that it can incorporate the currently available data without making a large number of assumptions around the data.
引用
收藏
页码:507 / 520
页数:14
相关论文
共 50 条
  • [21] The cost-effectiveness of telestroke in the treatment of acute ischemic stroke
    Nelson, R. E.
    Saltzman, G. M.
    Skalabrin, E. J.
    Demaerschalk, B. M.
    Majersik, J. J.
    NEUROLOGY, 2011, 77 (17) : 1590 - 1598
  • [22] COST-EFFECTIVENESS OF ACUTE ISCHEMIC STROKE IN CHINA: MARKOV MATRIX ANALYSES
    Wang, M.
    VALUE IN HEALTH, 2010, 13 (07) : A517 - A517
  • [23] COST-EFFECTIVENESS ANALYSES OF ACUTE ISCHEMIC STROKE CARE PATHWAYS: A MODEL FOR DIFFERENT SCENARIOS AND COUNTRIES
    de Greef, B.
    Youn, J. H.
    Baviere, H. Vanden
    Hummel, M.
    VALUE IN HEALTH, 2024, 27 (12)
  • [24] Model-based Evaluations of the Cost-effectiveness of Interventions for Lung Cancer: A Systematic Review
    Needham, K. J.
    Tappenden, P.
    Gillespie, D.
    Whyte, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S134 - S134
  • [25] A Model-Based Estimate of the Cost-Effectiveness Threshold in Germany
    Gandjour, Afschin
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2023, 21 (04) : 627 - 635
  • [26] A Model-Based Estimate of the Cost-Effectiveness Threshold in Germany
    Afschin Gandjour
    Applied Health Economics and Health Policy, 2023, 21 : 627 - 635
  • [28] Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis
    Norum, J.
    JOURNAL OF CHEMOTHERAPY, 2006, 18 (05) : 532 - 537
  • [29] A Systematic Review of Cost-Effectiveness Analyses for Hepatocellular Carcinoma Treatment
    Yuen, Sydney C.
    Amaefule, Adaeze Q.
    Kim, Hannah H.
    Owoo, Breanna-Verissa
    Gorman, Emily F.
    Mattingly, T. Joseph I. I. I. I.
    PHARMACOECONOMICS-OPEN, 2022, 6 (01) : 9 - 19
  • [30] A Systematic Review of Cost-Effectiveness Analyses for Hepatocellular Carcinoma Treatment
    Sydney C. Yuen
    Adaeze Q. Amaefule
    Hannah H. Kim
    Breanna-Verissa Owoo
    Emily F. Gorman
    T. Joseph Mattingly
    PharmacoEconomics - Open, 2022, 6 : 9 - 19